Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kairos Pharma Ltd (KAPA)

Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,033
  • Shares Outstanding, K 12,847
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,812 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3300 +27.82%
on 12/09/24
1.9200 -11.46%
on 12/13/24
+0.1000 (+6.25%)
since 11/22/24
3-Month
1.2200 +39.34%
on 10/01/24
2.7500 -38.18%
on 11/13/24
-0.3100 (-15.42%)
since 09/24/24

Most Recent Stories

More News
EF Hutton Provided ‘Buy’ Rating, $9.00 PT in Kairos Pharma (NYSE American: KAPA) Research Report

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, was featured in an EF Hutton report that initiated coverage with a...

KAPA : 1.7000 (-0.87%)
Kairos Pharma (NYSE American: KAPA) Receives ‘Buy’ Recommendation, $12.00 PT in Rodman & Renshaw Report

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, is spotlighted today in a Rodman & Renshaw, LLC report that initiated...

KAPA : 1.7000 (-0.87%)
Kairos Pharma to Participate in The Microcap Conference in January 2025

LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the...

KAPA : 1.7000 (-0.87%)
Kairos Pharma, Ltd. Announces Dual Listing on Upstream to Enhance Global Trading Opportunities

Kairos Pharma, Ltd. gains approval for dual listing on Upstream, enhancing global trading accessibility for investors.Quiver AI SummaryKairos Pharma, Ltd. announced the dual listing of its shares on Upstream,...

KAPA : 1.7000 (-0.87%)
Kairos Pharma Approved to Dual List on Upstream

KAPA : 1.7000 (-0.87%)
10 Stocks/Cryptos With Biggest Increases In Followers On Stocktwits Last Week

Dogecoin, SPY, Bitcoin, Ripple and Innovation Beverage were among the securities that drew retail attention last week.

MARA : 20.15 (+4.68%)
TSLA : 462.28 (+7.36%)
KAPA : 1.7000 (-0.87%)
BTCT : 5.02 (+11.06%)
SPY : 601.30 (+1.11%)
IBG : 1.0800 (+5.88%)
Kairos Pharma to Present at the LD Micro Main Event XVII

KAPA : 1.7000 (-0.87%)
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

KAPA : 1.7000 (-0.87%)

Business Summary

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based...

See More

Key Turning Points

3rd Resistance Point 1.8710
2nd Resistance Point 1.8208
1st Resistance Point 1.7604
Last Price 1.7000
1st Support Level 1.6498
2nd Support Level 1.5996
3rd Support Level 1.5392

See More

52-Week High 4.0000
Fibonacci 61.8% 2.9380
Fibonacci 50% 2.6100
Fibonacci 38.2% 2.2820
Last Price 1.7000
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar